Annual Review and Planning Meeting. No less frequently than annually, representatives of TKT and MMD shall meet at a place mutually agreed to by the parties (which, prior to the First Commercial Sale, will be one of the Research Committee or Development Committee Meetings)(the "Annual Meeting"), at which meeting MMD shall review the clinical, regulatory and marketing activities undertaken by MMD or its Affiliates since the previous Annual Meeting and shall present its clinical, regulatory and marketing plans for * for the ensuing year. Within 30 days following each Annual Meeting, MMD shall submit to TKT a written CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. report detailing the information reviewed and presented at such Annual Meeting.
Appears in 2 contracts
Samples: License Agreement (Transkaryotic Therapies Inc), License Agreement (Transkaryotic Therapies Inc)
Annual Review and Planning Meeting. No less frequently than annually, representatives of TKT and MMD shall meet at a place mutually agreed to by the parties (which, prior to the First Commercial Sale, will be one of the Research R&D Oversight Committee or Development Committee Meetings)(the meetings)(the "Annual Meeting"), at which meeting MMD shall review the clinical, regulatory and marketing activities undertaken by MMD or its Affiliates since the previous Annual Meeting and shall present its clinical, regulatory and marketing plans for * GA-EPO for the ensuing year. Within 30 days following each Annual Meeting, MMD shall submit to TKT a written CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS. report detailing the information reviewed and presented at such Annual Meeting.
Appears in 2 contracts
Samples: License Agreement (Transkaryotic Therapies Inc), License Agreement (Transkaryotic Therapies Inc)